02
Update on Rivaroxaban UK Proceedings: A Roller Coaster Ride for Generic Companies
In the United Kingdom, multiple generic competitors initiated invalidity lawsuits seeking revocation of Bayer’s key dosing patent protecting Xarelto 10, 15, and 20 mg (EP 1845961, the ‘961 patent; set to expire January 19, 2026) at the UK High Court (UKHC). In late March 2024, the UKHC granted Bayer’s request for a preliminary injunction against […]